ARDELYX, INC. (ARDX) Quick Ratio
- Quick ratio · latest quarter: Value 2.89×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 2.89× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $382.18M ÷ $132.22M ≈ 2.89× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 382.18M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 132.22M USD | Liabilities, Current |
| Cash and equivalents | 97.19M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 184.64M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 100.35M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 138.99M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $382.18M | $132.22M | $97.19M | $184.64M | $100.35M | $138.99M | 2.89× |
| 2026-03-31 | $320.91M | $109.57M | $31.21M | $206.87M | $82.84M | $128.03M | 2.93× |
| 2025-12-31 | $336.54M | $88.61M | $68.00M | $196.69M | $71.85M | $123.11M | 3.80× |
| 2025-09-30 | $319.31M | $83.39M | $42.72M | $199.99M | $76.61M | $129.36M | 3.83× |
| 2025-06-30 | $301.00M | $81.72M | $90.05M | $148.41M | $62.55M | $123.26M | 3.68× |
| 2025-03-31 | $260.42M | $75.84M | $30.81M | $183.14M | $46.47M | $105.88M | 3.43× |
| 2024-12-31 | $307.81M | $77.83M | $64.93M | $185.17M | $57.70M | $91.18M | 3.95× |
| 2024-09-30 | $243.60M | $70.50M | $47.43M | $142.97M | $53.20M | $85.16M | 3.46× |
| 2024-06-30 | $223.20M | $62.44M | $41.89M | $144.07M | $37.24M | $83.43M | 3.57× |
| 2024-03-31 | $230.74M | $56.90M | $36.15M | $166.43M | $28.16M | $78.86M | 4.06× |
| 2023-12-31 | $206.33M | $50.39M | $21.47M | $162.83M | $22.03M | $49.49M | 4.09× |
| 2023-09-30 | $208.34M | $43.53M | $33.77M | $131.31M | $43.26M | $47.50M | 4.79× |
| 2023-06-30 | $136.69M | $61.69M | $30.06M | $97.52M | $9.11M | $47.91M | 2.22× |
| 2023-03-31 | $142.49M | $63.06M | $92.49M | $37.89M | $12.12M | $44.95M | 2.26× |
| 2022-12-31 | $131.64M | $65.60M | $96.14M | $27.77M | $7.73M | $28.35M | 2.01× |
| 2022-09-30 | $95.83M | $51.95M | $61.63M | $29.00M | $5.21M | $9.77M | 1.84× |
| 2022-06-30 | $86.64M | $48.70M | $53.41M | $27.60M | $5.62M | $4.53M | 1.78× |
| 2022-03-31 | $94.10M | $47.84M | $47.08M | $42.63M | $4.39M | $3.49M | 1.97× |
| 2021-12-31 | $117.19M | $52.82M | $72.43M | $44.26M | $502.00K | (m) | 2.22× |
| 2021-09-30 | $141.94M | $68.77M | $75.29M | $66.36M | $287.00K | (m) | 2.06× |
| 2021-06-30 | (m) | $57.78M | $86.75M | $85.06M | (m) | (m) | (m) |
| 2021-03-31 | $184.00M | $41.79M | $84.07M | $94.14M | $5.78M | (m) | 4.40× |
| 2020-12-31 | (m) | $28.42M | $91.03M | $95.45M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $16.53M | $91.01M | $94.49M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $33.65M | $100.49M | $104.35M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $23.42M | $105.89M | $117.31M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $22.22M | $181.13M | $66.38M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $17.68M | $92.67M | $10.87M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $16.33M | $89.63M | $34.31M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $20.83M | $92.04M | $59.52M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $17.73M | $78.77M | $89.32M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $15.55M | $75.02M | $111.39M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $15.61M | $91.75M | $120.98M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $13.16M | $67.75M | $59.70M | (m) | (m) | (m) |
| 2018-01-02 | (m) | $1.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-01-01 | (m) | $1.00M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $17.87M | $75.38M | $58.59M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $15.73M | $59.45M | $69.83M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $18.39M | $63.64M | $85.09M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $19.31M | $71.21M | $102.21M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $19.20M | $74.60M | $126.22M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $17.64M | $160.36M | $69.73M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $14.06M | $146.67M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $12.46M | $171.68M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $7.72M | $107.00M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $12.58M | $129.05M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $5.55M | $141.53M | (m) | $27.00K | (m) | (m) |
| 2015-03-31 | (m) | $19.91M | $98.32M | (m) | $2.04M | (m) | (m) |
| 2014-12-31 | (m) | $21.54M | $107.29M | (m) | $2.58M | (m) | (m) |
| 2014-09-30 | (m) | $19.40M | $112.04M | (m) | $2.66M | (m) | (m) |
| 2014-06-30 | (m) | $27.33M | $117.81M | (m) | $3.02M | (m) | (m) |
| 2014-03-31 | (m) | (m) | $33.22M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $17.14M | $34.44M | (m) | $6.44M | (m) | (m) |
| 2013-09-30 | (m) | (m) | $23.53M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $23.75M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $32.90M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $10.78M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |